Incannex Healthcare — Expanding base with A$13m private placement

Incannex Healthcare (NASDAQ: IXHL)

Currency in USD

Last close As at 02/02/2023

USD3.24

−0.18 (−5.26%)

Market capitalisation

USD208m

Research: Healthcare

Incannex Healthcare — Expanding base with A$13m private placement

Incannex Healthcare has announced a fund-raise of A$13m (US$8.7m) in gross proceeds through a private placement to a healthcare-focused group of institutional investors. It will issue 63.4m new shares of common stock at A$0.205/share (a c 10.9% discount to the 2 December closing price). Proceeds of the raise will primarily be used to develop Incannex’s clinical pipeline (including assets acquired as part of APIRx acquisition). After the private placement, Incannex is expected to have a pro-forma cash position of around A$45m (US$30.6m) that, according to management, should be adequate to fund its operations into CY25. As a result of rolling our model forward, including newly issued shares and updating the cash position, we value Incannex at US$736.6m or US$11.7 per ADR.

Soo Romanoff

Written by

Soo Romanoff

Managing Director - Head of Content, Healthcare

incannex07

Healthcare

Incannex Healthcare

Expanding base with A$13m private placement

Financing update

Pharma and biotech

7 December 2022

Price

US$3.26

Market cap

US$205m

ADR/Ord conversion ratio 1:25

Pro forma net cash + gross proceeds (US$m) at 5 December 2022

30.6

ADRs in issue

63.0m

ADR code

IXHL

ADR exchange

NASDAQ-GM

Underlying exchange

ASX

Depository

DBK

Share price performance

%

1m

3m

12m

Abs

(16.9)

(26.6)

N/A

Rel (local)

(20.5)

(27.2)

N/A

52-week high/low

US$35.5

US$3.26

Business description

Incannex Healthcare is an Australian dual-listed biotech company focused on developing medicinal cannabis pharmaceutical products and psychedelic medicine therapies. These therapies are being designed to target indications with unmet need, including obstructive sleep apnea, generalized anxiety disorder, trauma and inflammatory conditions.

Next events

Phase IIa Psi-GAD interim data readouts

CY Q123

Open FDA IND for IHL-42X

CY Q123

Analysts

Soo Romanoff

+44 (0)20 3077 5700

Nidhi Singh

+44 (0)20 3077 5700

Dr Adam McCarter

+44 (0)20 3077 5700

Incannex Healthcare is a research client of Edison Investment Research Limited

Incannex Healthcare has announced a fund-raise of A$13m (US$8.7m) in gross proceeds through a private placement to a healthcare-focused group of institutional investors. It will issue 63.4m new shares of common stock at A$0.205/share (a c 10.9% discount to the 2 December closing price). Proceeds of the raise will primarily be used to develop Incannex’s clinical pipeline (including assets acquired as part of APIRx acquisition). After the private placement, Incannex is expected to have a pro-forma cash position of around A$45m (US$30.6m) that, according to management, should be adequate to fund its operations into CY25. As a result of rolling our model forward, including newly issued shares and updating the cash position, we value Incannex at US$736.6m or US$11.7 per ADR.

Year end

Revenue
(A$m)

PBT*
(A$m)

EPS*
(c)

DPS
(c)

P/E
(x)

Yield
(%)

06/21

2.0

(8.2)

(0.83)

0.0

N/A

N/A

06/22

0.8

(14.9)

(1.25)

0.0

N/A

N/A

06/23e

0.0

(20.6)

(1.35)

0.0

N/A

N/A

06/24e

0.0

(33.4)

(2.12)

0.0

N/A

N/A

Note: *PBT and EPS are normalised, excluding amortisation of acquired intangibles, exceptional items and share-based payments.

Attached options may extend cash runway

As part of the placement, subscribers will also be offered an equivalent number (63.4m) of new options, exercisable at A$0.285 per option. If fully exercised, these options may raise a further A$18.1m in proceeds. With the A$13.0m in gross proceeds from the current financing, excluding the effect of the attached options, we now expect Incannex will require A$55m in additional funding (from A$70m previously) before reaching profitability in FY26 with the launch of IHL-42X.

Busy clinical pipeline continues momentum

Although we had not anticipated any immediate financing requirements, Incannex’s raise comes at a crucial stage for the company with the upcoming investigational new drug (IND) application filing with the FDA in Q1 CY23 to initiate a pivotal Phase II/III study of its lead asset, IHL-42X. Incannex is looking to progress development of the assets from the APIRx pharmaceuticals acquisition, having recently announced it will start manufacturing its addiction treatments (CannQuit-N and CannQuit-O) and skin therapeutics (ReneCann) for use in upcoming clinical trials.

Valuation: US$736.6m or US$11.7 per ADR

We value Incannex at US$736.6m or US$11.7 per ADR (US$714.7m or US$11.74 per ADR previously). Our valuation has been affected by rolling our model forward three months and including the newly issued shares; however, our underlying long-term assumptions remain unchanged. Based on the company’s burn rate and our projections, we estimate the pro forma net cash position of A$45.0m at December 2022 provides a cash runway into CY25.

Exhibit 1: Financial summary

Accounts: IFRS, Yr end: June 30, AUD$:000s

 

 

2020

2021

2022

2023e

2024e

PROFIT & LOSS

 

 

 

 

 

 

 

Total revenues

 

 

822

1,973

789

77

79

Cost of sales

 

 

(450)

(912)

(6)

(6)

(6)

Gross profit

 

 

372

1,061

782

71

72

Total operating expenses

 

 

(4,301)

(9,225)

(15,686)

(20,678)

(33,482)

Research and development expenses

 

 

(2,111)

(4,750)

(5,372)

(9,848)

(21,600)

SG&A

 

 

(864)

(1,236)

(3,027)

(3,399)

(4,157)

Operating income (reported)

 

 

(3,929)

(8,164)

(14,904)

(20,607)

(33,409)

Finance income/(expense)

 

 

0

0

0

0

0

Exceptionals and adjustments

 

 

0

0

0

0

0

Net loss from discontinued operations

 

 

(768)

0

0

0

0

Profit before tax (reported)

 

 

(4,698)

(8,164)

(14,904)

(20,607)

(33,409)

Profit before tax (normalised)

 

 

(4,698)

(8,164)

(14,904)

(20,607)

(33,409)

Income tax expense (includes exceptionals)

 

 

0

0

0

0

0

Net income (reported)

 

 

(4,698)

(8,164)

(14,904)

(20,607)

(33,409)

Net income (normalised)

 

 

(4,698)

(8,164)

(14,904)

(20,607)

(33,409)

Basic average number of shares, m

 

 

684.0

978.0

1,191.2

1,525.0

1,574.0

Basic EPS (cents per share)

 

 

(0.69)

(0.83)

(1.25)

(1.35)

(2.12)

Adjusted EPS (cents per share)

 

 

(0.69)

(0.83)

(1.25)

(1.35)

(2.12)

Dividend per share (cents per share)

 

 

0.00

0.00

0.00

0.00

0.00

 

 

 

 

 

 

 

 

BALANCE SHEET

 

 

 

 

 

 

 

Tangible assets

 

 

0

0

0

0

0

Intangible assets

 

 

0

0

0

0

0

Right-of-use assets

 

 

0

0

0

0

0

Other non-current assets

 

 

0

0

0

0

0

Total non-current assets

 

 

0

0

0

0

0

Cash and equivalents

 

 

3,603

9,124

37,501

29,126

20,764

Current tax receivables

 

 

0

0

0

0

0

Trade and other receivables

 

 

413

169

295

292

307

Inventory

 

 

183

0

0

0

0

Other current assets

 

 

36

36

84

84

84

Total current assets

 

 

4,236

9,329

37,880

29,502

21,155

Non-current loans and borrowings

 

 

0

0

0

0

0

Non-current lease liabilities

 

 

0

0

0

0

0

Other non-current liabilities

 

 

0

0

0

0

0

Total non-current liabilities

 

 

0

0

0

0

0

Accounts payable

 

 

955

755

2,011

1,240

1,302

Illustrative debt

 

 

0

0

0

0

25,000

Current lease obligations

 

 

0

0

0

0

0

Other current liabilities

 

 

117

0

0

0

0

Total current liabilities

 

 

1,072

755

2,011

1,240

26,302

Equity attributable to company

 

 

3,164

8,574

35,869

28,262

(5,147)

 

 

 

0

0

0

0

0

CASH FLOW STATEMENT

 

 

 

 

 

 

 

Operating income

 

 

(4,698)

(8,164)

(14,904)

(20,607)

(33,409)

Depreciation and amortisation

 

 

37

0

0

0

0

Share based payments

 

 

565

1,172

1,465

0

0

Other adjustments

 

 

97

91

(594)

0

0

Movements in working capital

 

 

91

(10)

1,226

(768)

47

Cash from operations (CFO)

 

 

(3,907)

(6,910)

(12,807)

(21,375)

(33,362)

Capex

 

 

13

0

0

0

0

Acquisitions & disposals net

 

 

0

29

0

0

0

Other investing activities

 

 

0

0

0

0

0

Cash used in investing activities (CFIA)

 

 

13

29

0

0

0

Capital changes

 

 

7,469

12,401

41,185

13,000

0

Debt changes

 

 

(65)

0

0

0

25,000

Other financing activities

 

 

0

0

0

0

0

Cash from financing activities (CFF)

 

 

7,404

12,401

41,185

13,000

25,000

Cash and equivalents at beginning of period

 

 

93

3,603

9,124

37,501

29,126

Increase/(decrease) in cash and equivalents

 

 

3,510

5,520

28,377

(8,375)

(8,362)

Effect of FX on cash and equivalents

 

 

0

0

0

0

0

Cash and equivalents at end of period

 

 

3,603

9,124

37,501

29,126

20,764

Net (debt)/cash

 

 

3,603

9,124

37,501

29,126

20,764

Source: Incannex Healthcare, Edison Investment Research

General disclaimer and copyright

This report has been commissioned by Incannex Healthcare and prepared and issued by Edison, in consideration of a fee payable by Incannex Healthcare. Edison Investment Research standard fees are £60,000 pa for the production and broad dissemination of a detailed note (Outlook) following by regular (typically quarterly) update notes. Fees are paid upfront in cash without recourse. Edison may seek additional fees for the provision of roadshows and related IR services for the client but does not get remunerated for any investment banking services. We never take payment in stock, options or warrants for any of our services.

Accuracy of content: All information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable, however we do not guarantee the accuracy or completeness of this report and have not sought for this information to be independently verified. Opinions contained in this report represent those of the research department of Edison at the time of publication. Forward-looking information or statements in this report contain information that is based on assumptions, forecasts of future results, estimates of amounts not yet determinable, and therefore involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of their subject matter to be materially different from current expectations.

Exclusion of Liability: To the fullest extent allowed by law, Edison shall not be liable for any direct, indirect or consequential losses, loss of profits, damages, costs or expenses incurred or suffered by you arising out or in connection with the access to, use of or reliance on any information contained on this note.

No personalised advice: The information that we provide should not be construed in any manner whatsoever as, personalised advice. Also, the information provided by us should not be construed by any subscriber or prospective subscriber as Edison’s solicitation to effect, or attempt to effect, any transaction in a security. The securities described in the report may not be eligible for sale in all jurisdictions or to certain categories of investors.

Investment in securities mentioned: Edison has a restrictive policy relating to personal dealing and conflicts of interest. Edison Group does not conduct any investment business and, accordingly, does not itself hold any positions in the securities mentioned in this report. However, the respective directors, officers, employees and contractors of Edison may have a position in any or related securities mentioned in this report, subject to Edison's policies on personal dealing and conflicts of interest.

Copyright: Copyright 2022 Edison Investment Research Limited (Edison).

Australia

Edison Investment Research Pty Ltd (Edison AU) is the Australian subsidiary of Edison. Edison AU is a Corporate Authorised Representative (1252501) of Crown Wealth Group Pty Ltd who holds an Australian Financial Services Licence (Number: 494274). This research is issued in Australia by Edison AU and any access to it, is intended only for "wholesale clients" within the meaning of the Corporations Act 2001 of Australia. Any advice given by Edison AU is general advice only and does not take into account your personal circumstances, needs or objectives. You should, before acting on this advice, consider the appropriateness of the advice, having regard to your objectives, financial situation and needs. If our advice relates to the acquisition, or possible acquisition, of a particular financial product you should read any relevant Product Disclosure Statement or like instrument.

New Zealand

The research in this document is intended for New Zealand resident professional financial advisers or brokers (for use in their roles as financial advisers or brokers) and habitual investors who are “wholesale clients” for the purpose of the Financial Advisers Act 2008 (FAA) (as described in sections 5(c) (1)(a), (b) and (c) of the FAA). This is not a solicitation or inducement to buy, sell, subscribe, or underwrite any securities mentioned or in the topic of this document. For the purpose of the FAA, the content of this report is of a general nature, is intended as a source of general information only and is not intended to constitute a recommendation or opinion in relation to acquiring or disposing (including refraining from acquiring or disposing) of securities. The distribution of this document is not a “personalised service” and, to the extent that it contains any financial advice, is intended only as a “class service” provided by Edison within the meaning of the FAA (i.e. without taking into account the particular financial situation or goals of any person). As such, it should not be relied upon in making an investment decision.

United Kingdom

This document is prepared and provided by Edison for information purposes only and should not be construed as an offer or solicitation for investment in any securities mentioned or in the topic of this document. A marketing communication under FCA Rules, this document has not been prepared in accordance with the legal requirements designed to promote the independence of investment research and is not subject to any prohibition on dealing ahead of the dissemination of investment research.

This Communication is being distributed in the United Kingdom and is directed only at (i) persons having professional experience in matters relating to investments, i.e. investment professionals within the meaning of Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the "FPO") (ii) high net-worth companies, unincorporated associations or other bodies within the meaning of Article 49 of the FPO and (iii) persons to whom it is otherwise lawful to distribute it. The investment or investment activity to which this document relates is available only to such persons. It is not intended that this document be distributed or passed on, directly or indirectly, to any other class of persons and in any event and under no circumstances should persons of any other description rely on or act upon the contents of this document.

This Communication is being supplied to you solely for your information and may not be reproduced by, further distributed to or published in whole or in part by, any other person.

United States

Edison relies upon the "publishers' exclusion" from the definition of investment adviser under Section 202(a)(11) of the Investment Advisers Act of 1940 and corresponding state securities laws. This report is a bona fide publication of general and regular circulation offering impersonal investment-related advice, not tailored to a specific investment portfolio or the needs of current and/or prospective subscribers. As such, Edison does not offer or provide personal advice and the research provided is for informational purposes only. No mention of a particular security in this report constitutes a recommendation to buy, sell or hold that or any security, or that any particular security, portfolio of securities, transaction or investment strategy is suitable for any specific person.

Frankfurt +49 (0)69 78 8076 960

Schumannstrasse 34b

60325 Frankfurt

Germany

London +44 (0)20 3077 5700

280 High Holborn

London, WC1V 7EE

United Kingdom

New York +1 646 653 7026

1185 Avenue of the Americas

3rd Floor, New York, NY 10036

United States of America

Sydney +61 (0)2 8249 8342

Level 4, Office 1205

95 Pitt Street, Sydney

NSW 2000, Australia

Frankfurt +49 (0)69 78 8076 960

Schumannstrasse 34b

60325 Frankfurt

Germany

London +44 (0)20 3077 5700

280 High Holborn

London, WC1V 7EE

United Kingdom

New York +1 646 653 7026

1185 Avenue of the Americas

3rd Floor, New York, NY 10036

United States of America

Sydney +61 (0)2 8249 8342

Level 4, Office 1205

95 Pitt Street, Sydney

NSW 2000, Australia

General disclaimer and copyright

This report has been commissioned by Incannex Healthcare and prepared and issued by Edison, in consideration of a fee payable by Incannex Healthcare. Edison Investment Research standard fees are £60,000 pa for the production and broad dissemination of a detailed note (Outlook) following by regular (typically quarterly) update notes. Fees are paid upfront in cash without recourse. Edison may seek additional fees for the provision of roadshows and related IR services for the client but does not get remunerated for any investment banking services. We never take payment in stock, options or warrants for any of our services.

Accuracy of content: All information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable, however we do not guarantee the accuracy or completeness of this report and have not sought for this information to be independently verified. Opinions contained in this report represent those of the research department of Edison at the time of publication. Forward-looking information or statements in this report contain information that is based on assumptions, forecasts of future results, estimates of amounts not yet determinable, and therefore involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of their subject matter to be materially different from current expectations.

Exclusion of Liability: To the fullest extent allowed by law, Edison shall not be liable for any direct, indirect or consequential losses, loss of profits, damages, costs or expenses incurred or suffered by you arising out or in connection with the access to, use of or reliance on any information contained on this note.

No personalised advice: The information that we provide should not be construed in any manner whatsoever as, personalised advice. Also, the information provided by us should not be construed by any subscriber or prospective subscriber as Edison’s solicitation to effect, or attempt to effect, any transaction in a security. The securities described in the report may not be eligible for sale in all jurisdictions or to certain categories of investors.

Investment in securities mentioned: Edison has a restrictive policy relating to personal dealing and conflicts of interest. Edison Group does not conduct any investment business and, accordingly, does not itself hold any positions in the securities mentioned in this report. However, the respective directors, officers, employees and contractors of Edison may have a position in any or related securities mentioned in this report, subject to Edison's policies on personal dealing and conflicts of interest.

Copyright: Copyright 2022 Edison Investment Research Limited (Edison).

Australia

Edison Investment Research Pty Ltd (Edison AU) is the Australian subsidiary of Edison. Edison AU is a Corporate Authorised Representative (1252501) of Crown Wealth Group Pty Ltd who holds an Australian Financial Services Licence (Number: 494274). This research is issued in Australia by Edison AU and any access to it, is intended only for "wholesale clients" within the meaning of the Corporations Act 2001 of Australia. Any advice given by Edison AU is general advice only and does not take into account your personal circumstances, needs or objectives. You should, before acting on this advice, consider the appropriateness of the advice, having regard to your objectives, financial situation and needs. If our advice relates to the acquisition, or possible acquisition, of a particular financial product you should read any relevant Product Disclosure Statement or like instrument.

New Zealand

The research in this document is intended for New Zealand resident professional financial advisers or brokers (for use in their roles as financial advisers or brokers) and habitual investors who are “wholesale clients” for the purpose of the Financial Advisers Act 2008 (FAA) (as described in sections 5(c) (1)(a), (b) and (c) of the FAA). This is not a solicitation or inducement to buy, sell, subscribe, or underwrite any securities mentioned or in the topic of this document. For the purpose of the FAA, the content of this report is of a general nature, is intended as a source of general information only and is not intended to constitute a recommendation or opinion in relation to acquiring or disposing (including refraining from acquiring or disposing) of securities. The distribution of this document is not a “personalised service” and, to the extent that it contains any financial advice, is intended only as a “class service” provided by Edison within the meaning of the FAA (i.e. without taking into account the particular financial situation or goals of any person). As such, it should not be relied upon in making an investment decision.

United Kingdom

This document is prepared and provided by Edison for information purposes only and should not be construed as an offer or solicitation for investment in any securities mentioned or in the topic of this document. A marketing communication under FCA Rules, this document has not been prepared in accordance with the legal requirements designed to promote the independence of investment research and is not subject to any prohibition on dealing ahead of the dissemination of investment research.

This Communication is being distributed in the United Kingdom and is directed only at (i) persons having professional experience in matters relating to investments, i.e. investment professionals within the meaning of Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the "FPO") (ii) high net-worth companies, unincorporated associations or other bodies within the meaning of Article 49 of the FPO and (iii) persons to whom it is otherwise lawful to distribute it. The investment or investment activity to which this document relates is available only to such persons. It is not intended that this document be distributed or passed on, directly or indirectly, to any other class of persons and in any event and under no circumstances should persons of any other description rely on or act upon the contents of this document.

This Communication is being supplied to you solely for your information and may not be reproduced by, further distributed to or published in whole or in part by, any other person.

United States

Edison relies upon the "publishers' exclusion" from the definition of investment adviser under Section 202(a)(11) of the Investment Advisers Act of 1940 and corresponding state securities laws. This report is a bona fide publication of general and regular circulation offering impersonal investment-related advice, not tailored to a specific investment portfolio or the needs of current and/or prospective subscribers. As such, Edison does not offer or provide personal advice and the research provided is for informational purposes only. No mention of a particular security in this report constitutes a recommendation to buy, sell or hold that or any security, or that any particular security, portfolio of securities, transaction or investment strategy is suitable for any specific person.

Frankfurt +49 (0)69 78 8076 960

Schumannstrasse 34b

60325 Frankfurt

Germany

London +44 (0)20 3077 5700

280 High Holborn

London, WC1V 7EE

United Kingdom

New York +1 646 653 7026

1185 Avenue of the Americas

3rd Floor, New York, NY 10036

United States of America

Sydney +61 (0)2 8249 8342

Level 4, Office 1205

95 Pitt Street, Sydney

NSW 2000, Australia

Frankfurt +49 (0)69 78 8076 960

Schumannstrasse 34b

60325 Frankfurt

Germany

London +44 (0)20 3077 5700

280 High Holborn

London, WC1V 7EE

United Kingdom

New York +1 646 653 7026

1185 Avenue of the Americas

3rd Floor, New York, NY 10036

United States of America

Sydney +61 (0)2 8249 8342

Level 4, Office 1205

95 Pitt Street, Sydney

NSW 2000, Australia

More on Incannex Healthcare

View All

Latest from the Healthcare sector

View All Healthcare content

Research: TMT

4iG — Structuring the group for growth

4iG reported growth in pro forma EBITDA for Q322 and 9M22, despite the effect of cost inflation, new Hungarian supplementary telecom taxes and supply chain challenges, resulting in a pro forma EBITDA margin of 23.7% for 9M22 (9M21: 21.8%). During Q322, the company concentrated on integrating recent acquisitions and developing an organisational structure to support the group’s growth. Work continues on the Vodafone Hungary acquisition, which, when complete, will cement 4iG’s position as the number two telecom operator in Hungary.

Continue Reading

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free